Finance

Lists
Outlook: 44.4% bullish·5.6% bearish
Go to analysis
ILMN:NASDAQ
Illumina Inc
$264.57
-1.19%
(-3.19) 1D
$266.91
+0.88% (+2.34)
Pre-market
Closed: Oct 8, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ILMN...
Open
$263.69
High
$266.14
Low
$254.00
Mkt. cap
39.95B
Avg. vol.
3.58M
Volume
489.00
P/E ratio
49.18
52-wk high
$309.34
52-wk low
$88.00
EPS
$5.38
Beta
1.41
Shares outstanding
151.00M
No. of employees
9K
Open
$263.69
High
$266.14
Low
$254.00
Mkt. cap
39.95B
Avg. vol.
3.58M
Volume
489.00
P/E ratio
49.18
52-wk high
$309.34
52-wk low
$88.00
EPS
$5.38
Beta
1.41
Shares outstanding
151.00M
No. of employees
9K
News stories
From web sources and news partners
Profile
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries. Illumina's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Wikipedia
About Illumina Inc
CEOJacob Thaysen
Employees8.62K
Founded1998
HeadquartersSan Diego, California, United States
SectorHealth care
Websiteillumina.com
Analyst ratings
Based on 15 analysts giving stock ratings to ILMN in the past 3 months
Buy
Buy
8
Hold
4
Sell
3
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for ILMN in the last 3 months.
Highest
Current $264.57
$310.00 (+17.17%)
Average
$230.93 (-12.71%)
Lowest
$113.00 (-57.29%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luke Sergott
Barclays
Sell
Maintained
$200.00
-24.4%
10/07/2026
Dan Leonard
RBC Capital
Buy
Maintained
$310.00
+17.2%
10/04/2026
Subbu Nambi
Guggenheim
Buy
Maintained
$305.00
+15.3%
10/01/2026
Puneet Souda
Leerink Partners
Buy
Maintained
$300.00
+13.4%
09/29/2026
David Westenberg
Piper Sandler
Buy
Reiterated
$305.00
+15.3%
09/28/2026
Eve Burstein
Bernstein
Hold
Maintained
$215.00
-18.7%
09/25/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
$225.00
-15%
09/15/2026
Kyle Mikson CFA
Canaccord Genuity
Hold
Reiterated
-
-
09/11/2026
Unknown Analyst
UBS
Buy
Upgraded
$260.00
-1.7%
09/09/2026
Doug Schenkel
UBS
Buy
Upgraded
$260.00
-1.7%
09/09/2026
Jasper Hellweg
Argus Research
Buy
Maintained
$235.00
-11.2%
09/02/2026
Michael Ryskin
Bank of America Securities
Sell
Maintained
$140.00
-47.1%
08/05/2026
Ilya Zubkov
Freedom Capital Markets
Hold
Downgraded
$185.00
-30.1%
08/05/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
$230.00
-13.1%
08/04/2026
Patrick B Donnelly
Citi
Sell
Maintained
$113.00
-57.3%
08/03/2026
Daniel Brennan
TD Cowen
Hold
Reiterated
$210.00
-20.6%
07/31/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$200.00
-24.4%
07/06/2026
Tycho Peterson
Jefferies
Hold
Maintained
$150.00
-43.3%
07/01/2026
Unknown Analyst
RBC Capital
Buy
Initiated
$170.00
-35.7%
05/14/2026
Narumi Nakagiri
Daiwa
Buy
Upgraded
$155.00
-41.4%
05/14/2026
Catherine Ramsey Schulte
Robert W. Baird
Hold
Maintained
$137.00
-48.2%
02/06/2026
Last report
Jul 30, 2026
Fiscal period
Q2 2026
$1.31 / $1.23
+6.82%beat
Revenue / Est. (USD)
1.16B / 1.13B
+2.51%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.08B
1.16B
1.09B
1.16B
Cost of goods sold
335.00M
382.00M
353.00M
371.00M
Cost of revenue
335.00M
382.00M
353.00M
371.00M
Research and development expenses
228.00M
152.00M
240.00M
252.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
273.00M
381.00M
281.00M
273.00M
Operating expense
517.00M
549.00M
538.00M
543.00M
Total operating expenses
852.00M
931.00M
891.00M
914.00M
Operating income
232.00M
228.00M
200.00M
245.00M
Other non operating income
-
9.00M
10.00M
2.00M
EBT including unusual items
220.00M
377.00M
157.00M
260.00M
EBT excluding unusual items
216.00M
221.00M
197.00M
231.00M
Income tax expense
70.00M
43.00M
23.00M
53.00M
Effective tax rate
31.82%
11.41%
14.65%
20.38%
Other operating expenses
-
-
-
-
Net income
150.00M
334.00M
134.00M
207.00M
Net profit margin
13.84%
28.82%
12.28%
17.86%
Earnings per share
1.34
1.35
1.15
1.31
Interest and investment income
9.00M
10.00M
11.00M
8.00M
Interest expense
-25.00M
-26.00M
-24.00M
-24.00M
Net interest expenses
-16.00M
-16.00M
-13.00M
-16.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
299.00M
294.00M
269.00M
315.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps